You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Ovarian cancer

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

  • Technology appraisal guidance
  • Reference number: TA389
  • Published:  27 April 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Final scrutiny letter

Final scrutiny letter Final scrutiny letter
25 March 2015
(104.07 Kb 30 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 25 March 2015

Back to top